COMPANY
About Revance
Revance’s deep experience commercializing products for large pharmaceutical companies in highly competitive markets represents more than one hundred years of experience launching innovative products that change people’s lives.
COMPANY
About Revance
Revance is a biotechnology company setting the new standard in healthcare by elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings. Revance is an innovation leader in aesthetics and therapeutics.
More than one hundred years of experience
Revance’s deep experience commercializing products for large pharmaceutical companies in highly competitive markets represents more than one hundred years of experience launching innovative products that change people’s lives.
Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark and Irvine, California. Its technology hub is in Pleasanton, CA, and its commercial offices are in Irvine, CA.
Aesthetics
Building the Prestige Market
Revance Aesthetics is building a premium category in facial aesthetics, focused on differentiated and improved outcomes, a compelling value proposition and an elevated experience for physicians and patients. Our portfolio of expertly created products and services deliver a differentiated and exclusive offering for the company’s elite aesthetic partners and their patients.
Therapeutics
Now FDA Approved for the Treatment of Cervical Dystonia
revance
Revance by
the numbers
Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products
Year Founded
Years Invested in R&D
Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products
Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products
Employees
Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products
2022 Total Revenue
Revance is focused on meaningfully transforming patient and physician experiences with our aesthetics products
revance timeline
2002-2023
2002
Essentia Biosystems founded in a Silicon Valley think tank in Palo Alto, CA by Dan Browne, Michael Dake, M.D. and Jacob Waugh, M.D.
Founded to explore the potential use of peptides in the delivery of macromolecules for therapeutic diagnostic purposes connecting biologics and peptides such as immune modulators, insulin and botulinum toxins
2004
Moved to lab in garage in Mountain View, CA
2006
Renamed Revance Therapeutics, by then board member, Rowland Hansen, one of Bill Gates’ early hires who named Microsoft Windows
2007
Initiated clinical development for RT001, topical botulinum toxin type A gel, in lateral canthal lines
2008
Moved into Newark Headquarters in Biotech Bay
Initiated clinical development for RT001 topical formulation for axillary hyperhidrosis
2010
Manufacturing facility opened in Newark, CA
2012
Initiated clinical development for RT002 with first human subjects in Mexico
2014
Initiated clinical development for DaxibotulinumtoxinA for Injection in glabellar lines
RVNC NASDAQ IPO
Initiated clinical development for DaxibotulinumtoxinA for Injection in cervical dystonia and plantar fasciitis
2017
Positive results reported in SAKURA Phase 3 program in glabellar lines. Completion of 1st pivotal program for Revance
2018
Global collaboration and license agreement with Mylan for the development and commercialization of a proposed biosimilar to BOTOX®
*BOTOX® is a registered trademark of Allergan, Inc
Agreement with Fosun Pharma in China in aesthetics and therapeutics
2019
Mark J. Foley appointed President and CEO
BLA submitted for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines
Exclusive rights to the RHA® Collection of dermal fillers in the U.S.
2020
Positive results in two Phase 2a studies, forehead lines and lateral canthal lines
Acquired HintMD, first fintech platform in aesthetics
Advanced development program for biosimilar to BOTOX® with Viatris (previously Mylan)
*BOTOX® is a registered trademark of Allergan, IncLaunch of Revance Aesthetics
Hired first Revance Aesthetics sales force
Commerical Launch of RHA® 2, 3 and 4.
Positive results in ASPEN-1 Phase 3 trial in cervical dystonia
2021
Expanded National Footprint
Revance Global Headquarters and Experience Center moved to Nashville, TN
Positive results in JUNIPER Phase 2 trial in upper limb spasticity
First patient enrolled for DaxibotulinumtoxinA for Injection in glabellar lines and cervical dystonia in China
Relational Commerce Platform Launched
2022
Commercial Launch of RHA® Redensity™
FDA Approval of DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection
sBLA accepted for DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia
2023
DAXXIFY® Receives Second FDA Approval
Our products
Revance is setting the new standard in the aesthetic and therapeutics indications
Our prestige facial aesthetics portfolio, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection, the RHA® Collection of dermal fillers, and the OPUL™ financial technology (fintech) platform, offer a compelling value proposition and an elevated experience for physicians and patients. Revance’s innovative therapeutics program is driven by DAXXIFY®, which offers the first true innovation in neuromodulator formulation in over 30 years.
DAXXIFY® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION
Indications
(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
Adverse Reactions
The most commonly observed adverse reactions are:
Glabeller lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).
Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.
To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch
DAXI-004726
